Single supply chain. Documented end to end.

All flower entering the Phant supply chain is sourced from cultivators operating under Good Agricultural and Collection Practices, either certified or vetted to equivalent standards. Inputs are batch-identified at intake, sampled, and held in quarantine until release-grade testing is complete. Cultivar selection is led by clinical relevance — cannabinoid ratio, terpene profile, and lot-to-lot consistency — not retail trend.

Phant operates its own Health Canada-licensed manufacturing facility under Good Manufacturing Practice and Good Production Practice. Every step — milling, ice-water separation, pressing, formulation, fill, and finish — is performed in-house under documented batch records. In-process controls are taken at each stage; deviations are investigated and resolved against written procedures before product moves forward. Solventless extraction is the centre of the portfolio. Where solvents are used (live resin, distillate), the process is closed-loop and the residual solvent panel forms part of the release specification.

Every Phant batch is released against a full Certificate of Analysis. Testing is performed by independent ISO-accredited laboratories. The release panel includes:

• Cannabinoid profile (THC, THCa, CBD, CBDa, CBG, CBN, total cannabinoids)
• Terpene profile (full spectrum, dominant terpenes reported)
• Microbiology (aerobic count, yeast and mould, E. coli, Salmonella, Aspergillus species)
• Mycotoxins
• Heavy metals (lead, cadmium, mercury, arsenic)
• Residual solvents (where applicable)
• Pesticide residues
• Foreign matter and water activity Out-of-specification material does not leave the facility. Stability data is held against each format and is available to qualified clinical and procurement contacts on request.

Finished product moves under controlled conditions from release at the Phant facility to landed market. Shipments carry batch identifiers, release documentation, and the regulatory paperwork required by the destination jurisdiction. Each consignment is logged against the receiving licensed importer or medical distributor; any onward movement remains within the licensed channel. Cold-chain or controlled-temperature handling is applied where the product specification requires it.

Product distributed in the United Kingdom is released as a Cannabis-Based Product for Medicinal Use (CBPM) under Schedule 2 of the UK Misuse of Drugs Regulations 2001, in line with MHRA guidance for unlicensed CBPMs. Product distributed in Germany, the Czech Republic, South Africa, and Australia is released against the applicable medical cannabis framework in each jurisdiction. Documentation supplied with each consignment includes Certificate of Analysis, batch release certificate, manufacturing licence reference, and regulatory paperwork specific to the destination market.